Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations
Date:10/27/2010

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Oppenheimer 21st Annual Healthcare Conference in New York on November 2, 2010 at 11:25 a.m. Eastern time, and at the Lazard Capital Markets 7th Annual Healthcare Conference in New York on November 17, 2010 at 10 a.m. Eastern time.  The presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com. The webcasts will be available for 30 days following the events.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our finan
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
2. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
3. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
4. Neogen Acquires Gen-Probes BioKits Food Safety Business
5. Gen-Probe to Webcast Two Upcoming Investor Presentations
6. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
7. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
8. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 ... diversifies revenue base with highly profitable specialty products ... , Near-term growth potential with 11 product applications ... Paragraph IV certifications  , Provides medium and ... in development, including eight controlled substances , ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ... "Medical Device Studies: Clinical Evidence (London, UK - ... This course has been designed ... clinical evidence required for medical devices and in-vitro ... medical devices and the emphasis on high quality, ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... ( www.northernlight.com ) today announced a partnership ... that will let mutual customers directly search and access ... magazines, journals and other news sources through Northern Light ... subscribe to EBSCO,s Biomedical Reference Collection ((TM)) and ...
... Oct. 14 Sanofi Pasteur, the vaccines division ... ), announced today an interim analysis of data from clinical ... Vaccine in infants and children 6 months through 9 years ... and that one dose may protect many children. However, ...
Cached Medicine Technology:Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 2Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 3Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children 2Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children 3Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children 4Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children 5Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children 6
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... innovation and investment, announced the two leaders who will deliver keynote presentations at ... 3, at the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
(Date:9/2/2015)... ... 2015 , ... Healtec® LLC hired Stanley H. Salot Jr. ... former Chief Operations Officer. Shaun Carpenter MD, FAPWCA, CWSP , co-founder and ... Stanley H. Salot Jr , our new President and CEO, has nearly forty ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Good health ... Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New ... donation to the foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA ...
Breaking Medicine News(10 mins):Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:Healtec® Announces Executive Leadership Change 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... Institution in Washington, D.C. has joined Arizona State University ... sustaining a biodiverse planet. On Feb. 12, Secretary Wayne ... M. Crow launched a global classroom with one ... the tropical landscapes of Panama. The partnership ...
... , ... a leading provider of consumer driven telemedicine solutions announced that it closed a $5 million ... ... provider of consumer driven telemedicine solutions that drive down healthcare costs, announced that it closed ...
... ... to grow sales and reduce its impact on the environment. While renewing ... Foods, the largest Home Food service company in America, discovered they had ... once again measured and offset 100% of Service Foods’ scope 1 and ...
... ... year over year revenue growth. Unlimited use data room offer is the key driver. ... (PRWEB) February 16, 2010 -- ... secure extranets today announced that it had year over year revenue growth of 237%., , ...
... , , ... Bluestar Silicones is,launching a new line of TCS 7560 and ... lingerie and medical applications (support,stockings and medical equipment). These two ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20100216/377913 ) ...
... ... in compliance with SAS 70 recommended best practices related to internal controls. , ... Bellevue, WA (PRWEB) Feb. ... announced today that the company has received its completed SAS 70 Type II report. ...
Cached Medicine News:Health News:Smithsonian Institution, Arizona State University announce education and research partnership 2Health News:Consult A Doctor Closes $5 Million VC Round 2Health News:Consult A Doctor Closes $5 Million VC Round 3Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 2Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 4Health News:Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications 2Health News:Corporate Wellness Firm Limeade Receives SAS 70 Type II Report 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: